Fluvastatin

An indole-heptanoic acid derivative that inhibits HMG COA REDUCTASE and is used to treat HYPERCHOLESTEROLEMIA. In contrast to other statins, it does not appear to interact with other drugs that inhibit CYP3A4.

Also Known As:

7-(3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-6-heptenoate; Fluindostatin; Fluvastatin Sodium; Fluvastatin Sodium Salt; Lescol; XU 62-320; XU 62320; XU-62320; XU 62 320; XU62320; 6-Heptenoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, (3R,5S,6E)-

Networked: 810 relevant articles (88 outcomes, 244 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Holdaas, Hallvard: 13 articles (06/2014 - 06/2004)
2.	Penn, Linda Z: 8 articles (11/2021 - 12/2010)
3.	Fellström, Bengt: 8 articles (11/2009 - 06/2004)
4.	Kowalski, Jan: 8 articles (10/2006 - 04/2003)
5.	Ballantyne, C M: 8 articles (05/2001 - 01/2000)
6.	Šabovič, Mišo: 7 articles (09/2018 - 05/2014)
7.	Jardine, Alan G: 7 articles (06/2008 - 06/2004)
8.	Marian, A J: 7 articles (11/2002 - 01/2000)
9.	Longo, Joseph: 5 articles (11/2021 - 01/2018)
10.	Eržen, Barbara: 5 articles (09/2018 - 09/2013)

Related Diseases

1.	Hypercholesterolemia 09/01/1998 - "Fluvastatin is confirmed as effective and safe for the treatment of moderate hypercholesterolemia in the general-practice patient." 07/13/1995 - "In conclusion, long-term treatment of hypercholesterolemia with fluvastatin at dosages of 20-40 mg daily can be considered both safe and effective." 07/01/1998 - "To assess the efficacy of fluvastatin administered every other day versus an equivalent dose given daily in patients with hypercholesterolemia. " 01/01/2011 - "Long-term event monitoring study of fluvastatin in Japanese patients with hypercholesterolemia: Efficacy and incidence of cardiac and other events in elderly patients (≥ 65 years old)." 01/01/2006 - "In this prospective, double-blind, multicenter, multiple dose study, 236 patients with type IIa/b hypercholesterolemia were randomized to receive fluvastatin XL, 80 mg, in the morning or evening for 8 weeks. "
2.	Hyperlipidemias (Hyperlipidemia) 09/01/2004 - "We attempted to clarify the efficacy of fluvastatin on hyperlipidemia in renal transplant recipients. " 04/01/2005 - "An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. " 01/01/2001 - "The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study." 03/01/1998 - "The study included 60 outpatients with hyperlipidemia who had received a constant dose of fluvastatin for at least 6 weeks. " 05/01/2008 - "The beneficial vascular effects of fluvastatin persisted for a long period in patients with CAD and hyperlipidemia. "
3.	Neoplasms (Cancer) 06/01/2021 - "In line with NCI's emphasis to repurpose low-toxicity drugs for prevention of cancer, fluvastatin was effective for prevention of TNBC and warrants further clinical testing. " 12/01/2023 - "Therapeutic trial of fluvastatin in a cell line xenograft model of canine mammary gland cancer." 09/01/2006 - "Cox regression analysis, adjusted for baseline covariates and stratified by study, revealed a hazard ratio for first cancer diagnosis of 0.812 [95% confidence interval (CI) 0.667-0.989; p = 0.037] for fluvastatin compared with placebo. " 09/01/2006 - "The aim of the present study was to investigate the risk of cancer associated with fluvastatin treatment in clinical trials. " 03/01/1999 - "The objective of the study was to determine the maximal tolerated doses (MTD) and toxic effects of fluvastatin in pediatric cancer patients. "
4.	Type 2 Diabetes Mellitus (MODY) 01/01/1994 - "In this preliminary report of a 20-week trial, 66 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipidaemia who remained eligible after an 8-week dietary stabilization phase were randomly allocated to receive 20 mg of fluvastatin or placebo once daily for 6 weeks. " 12/01/2002 - "In patients with atherogenic dLDL, absolute changes of dLDL were most pronounced, emphasizing the value of fluvastatin treatment in type 2 diabetes. " 08/01/2002 - "Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus." 10/15/1999 - "Effects of fluvastatin on prothrombotic and fibrinolytic factors in type 2 diabetes mellitus." 01/01/1994 - "Efficacy and safety of fluvastatin in hyperlipidaemic patients with non-insulin-dependent diabetes mellitus."
5.	Coronary Disease (Coronary Heart Disease) 01/01/2004 - "To test the effectiveness of fluvastatin, 40-80 mg, in reducing the occurrence of cardiac and all-cause mortality in patients with coronary heart disease (CHD). " 01/01/2004 - "Fluvastatin reduces cardiac mortality in patients with coronary heart disease." 11/01/2002 - "Fluvastatin provides a useful option in treating hypercholesterolaemia in patients at high risk of coronary heart disease." 05/01/1999 - "A more mature phenotype of blood mononuclear phagocytes is induced by fluvastatin treatment in hypercholesterolemic patients with coronary heart disease." 04/01/1999 - "Since fluvastatin was last reviewed in Drugs, trials have shown its efficacy in the secondary prevention of coronary heart disease (CHD) events and death and have expanded knowledge of its effects in primary CHD prevention and its mechanisms of activity. "

Related Drugs and Biologics

1.	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)
2.	Lipids
3.	Atorvastatin (Lipitor)
4.	Pravastatin (Pravachol)
5.	Lovastatin (Mevacor)
6.	Simvastatin (Zocor)
7.	oxidized low density lipoprotein
8.	LDL Cholesterol
9.	Cholesterol
10.	Fenofibrate (CiL)

Related Therapies and Procedures

1.	Therapeutics
2.	Percutaneous Coronary Intervention
3.	Secondary Prevention
4.	Oral Administration
5.	Heart Transplantation (Grafting, Heart)